Abstract
Background: The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain. Methods: Post-SARS-CoV-2 vaccination blood samples across multiple DMTs were tested for SARS-CoV-2 immunoglobulin G (IgG) response. Results: Three hundred twenty-two people with MS were included; 91.9% received an mRNA vaccine. Post-vaccination reactive IgG rates (IgG index > 1) were 40% for anti-CD20 (32/80 patients); 41% for sphingosine 1-phosphate receptor modulators (S1PRM, 16/39); and 100% for all other classes, including the no DMT group. Conclusion: Anti-CD20 therapies and S1PRMs reduce IgG response to SARS-CoV-2 vaccination; IgG response is preserved with other DMTs.
Original language | English (US) |
---|---|
Pages (from-to) | 1131-1137 |
Number of pages | 7 |
Journal | Multiple Sclerosis Journal |
Volume | 28 |
Issue number | 7 |
DOIs | |
State | Published - Jun 2022 |
Keywords
- MS PATHS
- Multiple sclerosis
- SARS-COV-2 vaccination
- disease-modifying therapy
- humoral immune response
- optimal management
ASJC Scopus subject areas
- Clinical Neurology
- Neurology